Introduction
HeartFlow is a cardiovascular diagnostics company founded in 2010 in Mountain View, California. John Farquhar is among its founders. The company’s flagship product, HeartFlow FFRct Analysis, creates a non-invasive assessment of coronary blood flow from standard CT angiography scans, using a combination of AI, image processing, and computational fluid dynamics to help clinicians decide whether a patient’s chest pain warrants invasive catheterization. HeartFlow is publicly traded on Nasdaq under the ticker HTFL, making it one of the relatively few pure-play cardiovascular AI diagnostics companies with regular public disclosures.
Stable chest pain evaluation is one of the highest-volume decision points in cardiology: clinicians must balance avoiding unnecessary invasive procedures against missing clinically significant coronary disease. HeartFlow’s FFRct Analysis targets that decision directly from imaging many patients already receive.
What the company does
HeartFlow takes CT angiography data — a non-invasive scan many patients already receive for chest pain evaluation — and reconstructs patient-specific coronary anatomy, then simulates blood flow to estimate fractional flow reserve (FFR) values non-invasively. Clinicians historically obtained FFR invasively during catheterization; HeartFlow’s value proposition is reducing unnecessary invasive procedures while identifying patients who do need them. The workflow integrates with hospital imaging systems and returns results that cardiologists use alongside clinical judgment, not as autonomous treatment decisions.
Who it serves
HeartFlow sells to health systems, cardiology practices, and imaging centers that manage stable chest pain pathways and want to reduce avoidable invasive angiography. Payers and hospital administrators care about HeartFlow because invasive catheterization is costly and carries procedural risk, while missed significant coronary disease carries its own morbidity. The product sits in a shared decision space between cardiologists, radiologists who acquire CT studies, and referring primary care physicians managing chest pain workups.
John Farquhar’s founding role connects HeartFlow to a computational cardiology lineage that predates the current generative AI cycle — the company’s core technology combines physics simulation with imaging AI rather than large language models.
Company background
HeartFlow was founded in 2010 in Mountain View by John Farquhar and colleagues pursuing computational approaches to coronary physiology. The company spent years validating FFRct Analysis through clinical trials and securing payer coverage — prerequisites that slow adoption in cardiovascular diagnostics but also create barriers to entry once evidence accumulates. Its public listing on Nasdaq (HTFL) gives researchers and analysts access to periodic financial and operational disclosures uncommon among private clinical AI vendors.
Mountain View situates HeartFlow in the same broader Silicon Valley medical technology ecosystem as other cardiovascular and imaging innovators, though HeartFlow’s commercial model depends on hospital cath lab and imaging center relationships rather than consumer technology channels.
Product and AI capabilities
HeartFlow FFRct Analysis applies deep learning and physics-based modeling to transform CT angiography into personalized flow maps. The AI components handle segmentation and anatomical reconstruction tasks that would be labor-intensive manually; computational fluid dynamics then estimates pressure and flow across coronary lesions. In December 2025, HeartFlow announced results from its FISH&CHIPS analysis covering 90,000 patients, described in its investor relations release as demonstrating prognostic power for FFRct-guided decision-making — a scale of real-world evidence that matters in a category where payer coverage decisions often hinge on outcomes data rather than technical performance alone.
Combining AI segmentation with physics simulation is a hybrid architecture: the AI handles pattern recognition on imaging data, while CFD applies established hemodynamic principles to produce FFR estimates clinicians recognize from invasive cardiology practice.
Key developments
2010: HeartFlow founded in Mountain View. Public company: Nasdaq ticker HTFL. December 2025: HeartFlow announced FISH&CHIPS analysis of 90,000 patients per investor relations news release, highlighting prognostic evidence for FFRct Analysis.
The FISH&CHIPS label reflects HeartFlow’s framing of a large real-world outcomes dataset — the kind of evidence payers and guidelines committees typically request before expanding coverage beyond early-adopter centers.
Why it matters
HeartFlow matters because coronary artery disease remains one of the largest drivers of diagnostic imaging volume worldwide, and because non-invasive AI-augmented physiology assessment could materially change how chest pain pathways are managed if evidence and coverage continue to expand. Its public status (HTFL) makes it a rare company where investors and clinical readers can cross-check marketing claims against SEC filings. The 90,000-patient FISH&CHIPS dataset, disclosed in December 2025, is a concrete scale marker in a sector where “trained on millions of images” claims are often unverifiable.
HeartFlow’s public listing also makes it a bellwether for investor sentiment toward cardiovascular AI diagnostics — a category where reimbursement progress is slower than software but stickier once achieved.
Sector context
HeartFlow belongs in Brel’s AI in healthcare coverage under cardiology imaging, alongside Cleerly (plaque analysis from CT) and device-adjacent monitoring companies such as Eko Health. Readers comparing coronary AI should note HeartFlow’s physiology focus (flow) versus Cleerly’s plaque characterization focus (structure) — complementary but distinct clinical questions.
Sources and references
HeartFlow investor relations release on FISH&CHIPS 90,000-patient analysis (December 2025) and company website.
- HeartFlow IR — FFRct Analysis prognostic analysis (ir.heartflow.com, December 2025)
- HeartFlow — Company website (heartflow.com)